Literature DB >> 8622227

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.

R E Schmieder1, P Martus, A Klingbeil.   

Abstract

OBJECTIVE: To determine the ability of various antihypertensive agents to reduce left ventricular hypertrophy, a strong, blood pressure-independent cardiovascular risk factor, in persons with essential hypertension. DATA SOURCES: MEDLINE, DIMDI, RINGDOC, ADES, EMBASE, and review articles through July 1995 (English-language and full articles only). STUDY SELECTION: Meta-analysis of all published articles including only double-blind, randomized, controlled clinical studies with parallel-group design. DATA EXTRACTION: Intensive literature search and data extraction according to a prefixed scheme performed independently by 2 investigators. Reduction of left ventricular mass index after antihypertensive therapy with placebos, diuretics, beta-blockers, calcium channel blockers, or angiotensin-converting enzyme (ACE) inhibitors was the principal parameter. DATA SYNTHESIS: Of 471 identified references describing the effects of antihypertensive drugs on left ventricular hypertrophy, only 39 clinical trials fulfilled the inclusion criteria of our study. We found that the decrease in left ventricular mass index was more marked the greater was the decline in blood pressure (systolic r=0.46, P<.001; diastolic r=0.21, P=.08) and the longer was the duration of therapy (r=0.38, P<.01). After adjustment for different durations of treatment (mean duration of treatment, 25 weeks), left ventricular mass decreased 13% with ACE inhibitors, 9% with calcium channel blockers, 6% with beta-blockers, and 7% with diuretics. There was a significant difference between drug classes (P<.01): ACE inhibitors reduced left ventricular mass more than beta-blockers (significant, P<.05) and diuretics (tendency, P=.08). Similar differences between drug classes were found with regard to effect on left ventricular wall thickness (P<.05).
CONCLUSIONS: The database of articles published through July 1995 is small and incomplete, and most of the articles are of poor scientific quality. In this first meta-analysis including only double-blind, randomized, controlled clinical studies, decline in blood pressure, duration of drug treatment, and drug class determined the reductions in left ventricular mass index. The ACE inhibitors seemed to be more potent than beta-blockers and diuretics in the reduction of left ventricular mass index; calcium channel blockers were somewhat in the intermediate range. The ACE inhibitors and, to a lesser extent, calcium channel blockers emerged as first-line candidates to reduce the risk associated with left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622227

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  89 in total

1.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy.

Authors:  C J Friddle; T Koga; E M Rubin; J Bristow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

3.  Left ventricular hypertrophy: unresolved issues.

Authors:  J A Schoenberger
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 4.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 6.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 7.  Echocardiographic quantification of left ventricular mass: prognostic implications.

Authors:  Rajiv S Swamy; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

Review 8.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 9.  In hypertension, the kidney breaks your heart.

Authors:  Steven D Crowley; Thomas M Coffman
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 10.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.